Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor
Clement Opoku-Temeng1, Neetu Dayal, Delmis E Hernandez
1Chemistry Department, Institute for Drug Discovery, Purdue University, West Lafayette, IN 47907, USA. hsintim@purdue.edu.
Chemical Communications (Cambridge, England)
|April 10, 2018
Summary
A novel compound, HSD992, targets specific cyclin-dependent kinases (CDKs) crucial for cancer progression. This compound effectively inhibits cancer cell growth by targeting CDK2/3.
Area of Science:
- Medicinal Chemistry
- Oncology
- Molecular Biology
Background:
- Cyclin-dependent kinases (CDKs) play critical roles in cell cycle regulation.
- Dysregulation of CDKs is a hallmark of many cancers, making them attractive therapeutic targets.
- Developing selective CDK inhibitors is a key strategy in cancer drug discovery.
Purpose of the Study:
- To investigate the potential of HSD992 as a novel cancer therapeutic agent.
- To characterize the inhibitory profile of HSD992 against specific cyclin-dependent kinases.
- To evaluate the efficacy of HSD992 in inhibiting cancer cell proliferation.
Main Methods:
- Synthesis of HSD992, a compound featuring a tetrahydro-3H-pyrazolo[4,3-a]phenanthridine core.
- In vitro kinase assays to determine the inhibitory activity of HSD992 against various CDKs.
- Cell-based assays to assess the antiproliferative effects of HSD992 on human cancer cell lines.
Main Results:
- HSD992 demonstrated potent and selective inhibition of CDK2 and CDK3.
- HSD992 did not significantly inhibit other tested CDK family members, indicating target specificity.
- The compound exhibited significant antiproliferative activity across several tested cancer cell lines.
Conclusions:
- HSD992 represents a promising novel scaffold for the development of targeted cancer therapies.
- Selective inhibition of CDK2/3 by HSD992 offers a potential therapeutic strategy for cancers driven by these kinases.
- Further preclinical studies are warranted to explore the full therapeutic potential of HSD992 in oncology.
Related Concept Videos
02:34Inhibition of Cdk Activity
6.0K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.0K
02:38S-Cdk Initiates DNA Replication
5.7K
The cell cycle is a series of events leading to DNA duplication followed by the division of cell content to form two daughter cells. The cell cycle progresses in four stages—the cell increases in size (gap 1 or G1-phase), duplicates its DNA (synthesis or S-phase), prepares to divide (gap 2 or G2-phase), and divides (mitosis or M-phase).
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
Two states at the origin of replication
In eukaryotes, the initiation of replication occurs at many sites on the chromosomes, called the origins of...
5.7K
02:15M-Cdk Drives Transition Into Mitosis
6.6K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.6K
01:52Eukaryotic Transcription Inhibitors
11.1K
Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
11.1K
01:23Dipeptidyl Peptidase 4 Inhibitors
693
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
693
01:25Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K